BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 215 filers reported holding BRIDGEBIO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $912,402 | -71.3% | 34,600 | -81.3% | 0.01% | -66.7% |
| Q2 2023 | $3,183,084 | -12.2% | 185,063 | -15.4% | 0.02% | -4.5% |
| Q1 2023 | $3,625,151 | +6769.8% | 218,646 | +3057.3% | 0.02% | – |
| Q4 2022 | $52,769 | -98.8% | 6,925 | -98.5% | 0.00% | -100.0% |
| Q3 2022 | $4,562,000 | +108.5% | 458,936 | +90.4% | 0.03% | +100.0% |
| Q2 2022 | $2,188,000 | -12.6% | 240,996 | -2.3% | 0.01% | -38.1% |
| Q1 2022 | $2,504,000 | +137.1% | 246,731 | +289.8% | 0.02% | +110.0% |
| Q4 2021 | $1,056,000 | +93.8% | 63,292 | +443.9% | 0.01% | +42.9% |
| Q3 2021 | $545,000 | +137.0% | 11,636 | +211.3% | 0.01% | +133.3% |
| Q1 2021 | $230,000 | -59.2% | 3,738 | -52.8% | 0.00% | -62.5% |
| Q4 2020 | $564,000 | -47.8% | 7,926 | -72.5% | 0.01% | -50.0% |
| Q3 2020 | $1,081,000 | – | 28,801 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |